Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Misgivings About Reprints Would Not Make Them "False" - WLF Lawyer

This article was originally published in The Gray Sheet

Executive Summary

FDA would not be permitted to object to off-label reprints as "false and misleading" because the agency has technical problems with an article under the recent Washington Legal Foundation v. Henney ruling on off-label dissemination, Daniel Troy of the Washington D.C. law firm of Wiley, Rein & Fielding, asserted.
Advertisement

Related Content

WLF Decision Opens Door To Off-Label Promotion With Journal Reprints
WLF Decision Opens Door To Off-Label Promotion With Journal Reprints
Advertisement
UsernamePublicRestriction

Register

MT012196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel